 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Simulations Plus, Inc. (SLP) develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. 
It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft.
The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.
It also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems pharmacology software; NAFLDsym; IPFsym; RENAsym; and MITOsym. In addition, the company provides Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus.
Further, it provides population modeling and simulation contract research services; training and consulting services designed to accelerate pharmacometrics studies; and clinical-pharmacology-based consulting services in support of regulatory submissions.
The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies.
Shares are heading higher following an upward trendline. On July 6th, SLP reported 3rd Quarter May 2022 earnings of $0.20 per share on revenue of $15.0 million. The consensus earnings estimate was $0.17 per share on revenue of $14.3 million. Revenue grew 17.1% on a year-over-year basis.
The company said it expects fiscal 2022 revenue of $52.0 million to $53.0 million. The company's previous guidance was revenue of $51.0 million to $53.0 million and the current consensus revenue estimate is $52.90 million for the year ending August 31, 2022. Higher share prices are expected.
Entry Point: $65.00
Trading Range: $35.18 to $66.68
Stop Loss: $61.50
Target Price: $71.50
SLP closed at $60.50
